Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial.

Abstract

OBJECTIVE We compared variations among Canadian provinces in rheumatoid arthritis (RA) initiating anti-tumor necrosis factor (TNF) therapy. METHODS Data were obtained from the Optimization of Humira trial (OH) and from the Ontario Biologics Research Initiative (OBRI). Baseline characteristics were compared between regions: Ontario (ON), Quebec (QC), and… (More)
DOI: 10.3899/jrheum.091447

Topics

4 Figures and Tables

Cite this paper

@article{Pease2010CanadianVB, title={Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial.}, author={Christopher Pease and Janet Elizabeth Pope and Carter Thorne and Boulos Paul Haraoui and Don H Truong and Claire Bombardier and Jessica Widdifield and Eliofotisti Psaradellis and John S Sampalis and Ashley Bonner}, journal={The Journal of rheumatology}, year={2010}, volume={37 12}, pages={2469-74} }